News for Healthier Living

AOB Pharma Receives European Medicines Agency (EMA) Positive Decision on the Pediatric Investigation Plan (PIP), Supporting Future Development of B244 for the Treatment of Mild to Moderate Atopic Derm

B244, a first-in-class topical live biotherapeutic product, is currently planned for global Phase 3 development in mild to moderate atopic dermatitis and pruritus.

December 2, 2025


December 13 2025

December 12 2025

December 11 2025

December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025